Genetic Nondiscrimination in Canada

Canada’s parliament is set for a final vote on a proposed genetic nondiscrimination act.

Written byJoshua A. Krisch
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, SAFFRON BLAZECanada’s parliament threw its support behind bill S-201, legislation similar to the U.S. Genetic Information Nondiscrimination Act (GINA), which would fine insurers and employers for making decisions based on the results of genetic testing alone, according to The Hill Times. The bill passed a “third reading” on Wednesday night (March 8), the final chance for the House of Commons to debate its contents. The legislation will now return to the Senate for what many hope will be a final vote.

Under bill S-201, it would be illegal to force Canadian citizens to undergo genetic testing or provide results to insurance companies or employers. As with GINA, the main opposition is that the bill would be a blow to insurance companies and could raise premiums across the board, if insurers are required to assume more risk. Prime Minister Justin Trudeau has opposed the bill, telling reporters that “one of the elements in the proposed bill is unconstitutional,” according to Global News.

Specifically, some members of Trudeau’s Liberal Party believe the bill is an act of government overreach. They have proposed taking less drastic steps, such as amending the Canadian Human Rights Act to prohibit discrimination based on genetics in place of passing new legislation.

Advocates of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies